| Literature DB >> 33775706 |
Matthew A Borrelli1, Heth R Turnquist2, Steven R Little3.
Abstract
Cardiovascular disease is the leading cause of death around the world, in which myocardial infarction (MI) is a precipitating event. However, current therapies do not adequately address the multiple dysregulated systems following MI. Consequently, recent studies have developed novel biologic delivery systems to more effectively address these maladies. This review utilizes a scientometric summary of the recent literature to identify trends among biologic delivery systems designed to treat MI. Emphasis is placed on sustained or targeted release of biologics (e.g. growth factors, nucleic acids, stem cells, chemokines) from common delivery systems (e.g. microparticles, nanocarriers, injectable hydrogels, implantable patches). We also evaluate biologic delivery system trends in the entire regenerative medicine field to identify emerging approaches that may translate to the treatment of MI. Future developments include immune system targeting through soluble factor or chemokine delivery, and the development of advanced delivery systems that facilitate the synergistic delivery of biologics.Entities:
Keywords: Biologics; Chemokines; Controlled release; Drug delivery; Extracellular vesicle; Growth factors; Myocardial infarction; Nucleic acids; Scientometric review; Stem cells
Mesh：
Substances：
Year: 2021 PMID： 33775706 PMCID： PMC8178247 DOI： 10.1016/j.addr.2021.03.014
Source DB: PubMed Journal: Adv Drug Deliv Rev ISSN： 0169-409X Impact factor: 17.873